Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations


19.3   1.33 (7.4%) 02-28 16:00
Open: 16.86 Pre. Close: 17.97
High: 19.97 Low: 16.86
Volume: 433,476 Market Cap: 611M
AVROBIO, Inc., a clinical-stage gene therapy company, focuses on developing ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose in the United States. Its gene therapies employ hematopoietic stem cells that are collected from patients and modified with a lentiviral vector to insert functional copies of the gene, which is defective in the target disease. The company's lead product candidate is AVR-RD-01, which is in ongoing Phase II clinical trial and investigator-sponsored Phase I clinical trial for the treatment of Fabry disease. It is also developing AVR-RD-02 that has completed pre-clinical trials for the treatment of type 1 Gaucher disease; AVR-RD-03, which is in preclinical development to treat Pompe disease; and AVR-RD-04 that has completed pre-clinical studies for treating cystinosis. The company was founded in 2015 and is headquartered in Cambridge, Massachusetts.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 20.017 - 20.149 20.149 - 20.269
Low: 16.576 - 16.722 16.722 - 16.855
Close: 19.045 - 19.305 19.305 - 19.54

Technical analysis

as of: 2020-02-28 4:26:30 PM
Stoxline posted a NEUTRAL today, upgraded from lower rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell.
Target: Six months: 28.64     One year: 34.25
Support: Support1: 16.76    Support2: 13.94
Resistance: Resistance1: 24.52    Resistance2: 29.32
Pivot: 22.57
Moving Average: MA(5): 19.26     MA(20): 22.56
MA(100): 18.37     MA(250): 18.20
MACD: MACD(12,26): -0.60     Signal(9): 0.17
Stochastic oscillator: %K(14,3): 12.43     %D(3): 9.67
RSI: RSI(14): 42.07
52-week: High: 29.32  Low: 12.67  Change(%): 20.9
Average Vol(K): 3-Month: 31338  10-Days: 46131

Price, moving averages and Bollinger Bands

Price and moving averages has closed below its Short term moving average. Short term moving average is currently above mid-term; AND above long term moving averages. From the relationship between price and moving averages; we can see that: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
AVRO has closed above bottom band by 21.5%. Bollinger Bands are 145.8% wider than normal. The large width of the bands suggest high volatility as compared to AVRO's normal range. The bands have been in this wide range for 13 bars. This is a sign that the current trend might continue.

Headline News

AVROBIO to Present at the Cowen and Company 40th Annual Health Care Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (NASDAQ: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced Geoff MacKay, president and CEO of AVROBIO, will present at the Cowen and Company 40th Annual Health Care Conference at 4:50 p.m. ET on Monday, March 2, 2020, at the Boston Marriott Copley Place, Boston. A live webcast of the presentation can be accessed under "Events and Presentations" in the Investors &

AVROBIO Announces Closing of Underwritten Public Offering
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (NASDAQ:AVRO), a leading clinical-stage gene therapy company, today announced the closing of its previously announced underwritten public offering of 4,350,000 shares of its common stock. The aggregate gross proceeds to the company from the offering, before deducting underwriting discounts and commission and estimated offering expenses, totaled approximately $100 million. As previously announced, the company has granted the underwriters a 30-day

Financial Analysis

Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.
Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs.
Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.
Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.
Click here to get more fundamental analysis.
Tweet this page Share on Facebook
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NasdaqGS
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. (M) 31.67
Shares Float (M) 23.50
% Held by Insiders 2.71
% Held by Institutions 97.64
Shares Short (K) 1610
Shares Short P. Month (K)

Stock Financials

EPS -2.600
Book Value (p.s.) 6.540
PEG Ratio
Profit Margin
Operating Margin
Return on Assets (ttm) -23.9
Return on Equity (ttm) -38.6
Qtrly Rev. Growth
Gross Profit (p.s.)
Sales Per Share
EBITDA (p.s.) -2.155
Qtrly Earnings Growth
Operating Cash Flow (M) -60.52
Levered Free Cash Flow (M) -39.44

Stock Valuations

P/E -7.42
P/E Growth Ratio 0.07
P/BV 2.95
P/CF -10.10

Dividends & Splits

Dividend Yield
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Forward Dividend
Last Split Date
Last Split Ratio -1e+010
7 Binary Options
Your Ad Here
Stock Chart
Stoxline Lite
Stoxline Pro
Option Calculator
(c) 2006-2019 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.